Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to identify risk factors for their occurrence. Among 571 newly diagnosed AML patients, 26 (4.6%) developed fatal cardiac events, and among 525 treated patients, 19 (3.6%) experienced fatal cardiac events (CI: 2% at 6 months; 6.7% at 9 years). Prior heart disease was associated with the development of fatal cardiac events (hazard ratio (HR) = 6.9). The CI of non-fatal cardiac events was 43.7% at 6 months and 56.9% at 9 years. Age ≥ 65 (HR = 2.2), relevant cardiac antecedents (HR = 1.4), and non-intensive chemotherapy (HR = 1.8) were associated with non-fatal cardiac events. The 9-year CI of grade 1-2 QTcF prolongation was 11.2%, grade 3 was 2.7%, and no patient had grade 4-5 events. The 9-year CI of grade 1-2 cardiac failure was 1.3%, grade 3-4 was 15%, and grade 5 was 2.1%; of grade 1-2, arrhythmia was 1.9%, grade 3-4 was 9.1%, and grade 5 was 1%. Among 285 intensive therapy patients, median overall survival decreased in those experiencing grade 3-4 cardiac events (p < 0.001). We observed a high incidence of cardiac toxicity associated with significant mortality in AML.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cancers - 15(2023), 8 vom: 12. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boluda, Blanca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
Date Revised 19.09.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers15082267 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356928462 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356928462 | ||
| 003 | DE-627 | ||
| 005 | 20231226071510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15082267 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356928462 | ||
| 035 | |a (NLM)37190195 | ||
| 035 | |a (PII)2267 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boluda, Blanca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to identify risk factors for their occurrence. Among 571 newly diagnosed AML patients, 26 (4.6%) developed fatal cardiac events, and among 525 treated patients, 19 (3.6%) experienced fatal cardiac events (CI: 2% at 6 months; 6.7% at 9 years). Prior heart disease was associated with the development of fatal cardiac events (hazard ratio (HR) = 6.9). The CI of non-fatal cardiac events was 43.7% at 6 months and 56.9% at 9 years. Age ≥ 65 (HR = 2.2), relevant cardiac antecedents (HR = 1.4), and non-intensive chemotherapy (HR = 1.8) were associated with non-fatal cardiac events. The 9-year CI of grade 1-2 QTcF prolongation was 11.2%, grade 3 was 2.7%, and no patient had grade 4-5 events. The 9-year CI of grade 1-2 cardiac failure was 1.3%, grade 3-4 was 15%, and grade 5 was 2.1%; of grade 1-2, arrhythmia was 1.9%, grade 3-4 was 9.1%, and grade 5 was 1%. Among 285 intensive therapy patients, median overall survival decreased in those experiencing grade 3-4 cardiac events (p < 0.001). We observed a high incidence of cardiac toxicity associated with significant mortality in AML | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a cardiac toxicity | |
| 650 | 4 | |a real-life | |
| 650 | 4 | |a risk factors | |
| 700 | 1 | |a Solana-Altabella, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Cano, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Cuadrón, David |e verfasserin |4 aut | |
| 700 | 1 | |a Acuña-Cruz, Evelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Miñana, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Veiga, Rebeca |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro-Vicente, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Campuzano, David |e verfasserin |4 aut | |
| 700 | 1 | |a García-Ruiz, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Lloret, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Asensi, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Osa-Sáez, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Aguero, Jaume |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Serrano, María |e verfasserin |4 aut | |
| 700 | 1 | |a Buendía-Fuentes, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Megías-Vericat, Juan Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Herreros, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Barragán, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Sargas, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Salas, Maribel |e verfasserin |4 aut | |
| 700 | 1 | |a Wooddell, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Dharmani, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a De la Rubia, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Montesinos, Pau |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2023), 8 vom: 12. Apr. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:8 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15082267 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 8 |b 12 |c 04 | ||